Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): a randomized, observer-blinded, placebo-controlled trial

1.1 Pathogen

2019 Novel Coronavirus 2019(SARS-CoV-2) belongs to the genus β of coronavirus, with enveloped granules that are round or elliptic, often pleomorphic, with diameters ranging from 60 nm to 140nm. Its genetic characteristics are significantly different from those of SARS-CoV and MERS-CoV.

SARS-CoV-2 Coronaviruses belong to the genus Coronavirus in the family Coronaviridae. Coronaviruses are single-stranded RNA viruses with an envelope. They are a large group of viruses that exist widely in nature. Globally, 10% to 30% of upper respiratory tract infections are caused by HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1, which are the second leading cause of the common cold, after rhinoviruses. Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), caused by coronavirus, are known to be serious infectious diseases.

The coronavirus genome encodes spike protein (S), envelope protein (E), membrane protein (M) and nucleoprotein (N) in sequence. Among them, S protein is the most important surface protein of coronavirus, which is related to the transmission ability of the virus. S protein contains two subunits: S1 and S2. S1 mainly contains receptor binding region, which is responsible for the recognition of cellular receptors. S2 contains the basic elements for the membrane fusion process. In the previous development of SARS and MERS vaccines, S protein was used as the most important candidate antigen.

1.2 Disease and epidemiological background

The COVID-19 is mainly characterized by fever, dry cough and fatigue. A small number of patients have symptoms such as nasal congestion, runny nose, sore throat, myalgia and diarrhea. Severe patients usually develop dyspnea and/or hypoxemia one week after onset, and in severe cases, rapid progression to acute respiratory distress syndrome, septic shock, refractory metabolic acidosis, haemorrhagic dysfunction and multiple organ failure, etc. It is worth noting that the course of the disease in the severe and critical patients may be moderate to low fever, or even no obvious fever. Some children and newborns showed atypical symptoms, such as diarrhea, vomiting and other digestive tract symptoms, or only mental weakness and shortness of breath.

At present, the source of infection is mainly patients infected by SARS-CoV-2. An asymptomatic infected person may also be a source of infection. The main route of transmission is by respiratory droplets and close contact is the main route of transmission. Exposure to high concentrations of aerosols in a relatively closed environment for a long period of time has the potential for aerosol transmission. SARS-CoV-2 can be isolated from feces and urine, and attention should be paid to the aerosol or contact transmission caused by feces and urine to environmental pollution. The population is generally susceptible.

1.3 Basis of the study

Currently, there are five major platforms of COVID-19 vaccine worldwide, namely, inactivated vaccine, viral vectored vaccine, live attenuated vaccine, recombinant protein vaccine and nucleic acid vaccine. The inactivated COVID-19 vaccines are developed by China Biotechnology Technology Co., Ltd. and Sinovac Life Science Co., Ltd. and Recombinant adenovirus type 5 vectored (Ad5-nCoV) jointly developed by Military Academy of Military Medical Institute and CanSino Biologics Inc have got conditional approval on the market in China. In addition, protein-subunit-based COVID-19 vaccine (ZF2001), jointly developed by the Institute of Microbiology, Chinese Academy of Sciences and Anhui Zhifei Longcom Biopharmaceutical has been granted emergency use authorization from National Medcial Products Administration on March 2021.

Up to now, preliminary results from phase 3 clinical trials showed that the short-term protection rates of inactive vaccine developed by Sinovac and Ad5 vectored vaccine developed by CanSino were 50.4% and 65.7%, respectively. Although two vaccines met the requirement of WHO for the minimum protection rate of 50%, the protection rates were moderate. Comparing to the 95% protection rate of mRNA vaccine against COVID-19 developed by Moderna and Pfizer/ Biontech, the inactive vaccine and Ad5 vectored vaccine seemed to have a lower efficacy.

In order to induce a robust immune response, Russia deployed a heterologous prime-boost schedule using Ad26 and Ad5 vectored COVID-19 vaccine, which has shown 91.6% efficacy against COVID-19. The United Kingdom has also announced a heterologous prime-boost immunization study of adenovirus vectored COVID-19 vaccine and mRNA vaccine, with a view to optimizing the immunization program of the existing COVID-19 vaccine and achieving better protective effect in a short time.

Among different vaccine modalities, heterologous strategies have shown to enhance humoral and cellular responses in several animal models. However, there is lack of regulatory guidance on heterologous (cross-platform) prime-boost immunization. In theory, the types and characteristics of the immune response induced by Ad5 vectored vaccine and protein subunit vaccine deliver antigens through different vaccine components or vector types, and the prime-boost vaccination of the two vaccines at different time points may improve the quality of the immune response, and optimize the existing immunization strategies.

In this study, subjects who have completed a dose of Ad5 vectored COVID-19 vaccine will be enrolled again to receive a booster dose of COVID-19 recombinant protein subunit vaccine at 28 or 56 days after the prime dose, which forms a heterologous prime-boost immunization program. To evaluate the effect of immunogenicity after immunization, the subjects in each regimen will be randomly vaccinated with the booster dose of subunit vaccine(ZF2001) against COVID-19 or a commercial influenza vaccine in a ratio of 2:1. In addition, due to clinical trial (JSVCT093) with two doses of Ad5 vectored COVID-19 vaccine and the phaseⅠ/ Ⅱ clinical trial with three dose of recombinant protein subunit vaccine (CHO cells) in healthy adults prior to this study, their serum samples after last vaccination can be provided for parallel detection of immunogenicity data, to provide complete control data.

The clinical study protocol is formulated in accordance with the requirements of the Vaccine Administration Law, the Good Practice for Quality Management of Drug Clinical Trials (GCP), the Technical Guiding Principles for Quality Management of Vaccine Clinical Trials and the Guiding Principles for Quality Management of Vaccine Clinical Trials (Trial).

3.1 Design procedures

This study is a single center, randomized, observer blind, placebo-controlled heterologous prime-boost immunization clinical trial, with “0-28 days” and “0-56 days” immunization regimens. The subjects are divided into two age groups, i.e. 18-59 years and 60 years and above.

Stage 1: According to the “0-28 days” regimen, sixty eligible subjects (30 in each age group) meeting the protocol requirements will be randomly assigned in a 2:1 ratio to receive a RBD-based protein subunit vaccine (CHO) or placebo (influenza vaccine).

Stage 2: According to the “0-56 days” regimen, sixty eligible subjects (30 in each age group) meeting the protocol requirements will be randomly assigned in a 2:1 ratio to receive a RBD-based protein subunit vaccine (CHO) or placebo (influenza vaccine).

Stage 3: For 0-28 days regimen and 0-56 days regimen, all participants receive a boost vaccination with ZF2001 at 4 months after the 1st boost dose.

3.2 Study Endpoints

3.3 Study Plan

120 healthy subjects aged over 18 years of age who have who have received one dose of the Ad5 vectored COVID-19 vaccine in three batches consistence clinical trials will be recruited in this study. Of them, 60 subjects will be enrolled in the “0-28 days” regimen and other 60 will be enrolled in “0-56 days” regimen. Subjects in each regimen will be randomly assigned to receive the booster dose of subunit vaccine (ZF2001) against COVID-19 or a commercial influenza vaccine in a ratio of 2:1. For 0-28 days regimen and 0-56 days regimen, all participants receive a boost vaccination with ZF2001 at 4 months after the 1st boost dose.

The occurrence of adverse events within 28 days and serious adverse events within 6 months after vaccination will be observed. In addition, blood samples will be collected at baseline (at day 28 post primary dose), and at day 14, day 28 post 1^st booster dose, and at day 14 and month 6 after the 2^nd booster vaccination to test serum antibody levels and to profile the specific memory immune cells and antibody repertoire. Each subject will remain in this study for approximately 12 months.

In “0-28 days” regimen, participants will attend 9 visits in total, including V0 (day 28 after the prime dose, the 1^st booster vaccination), V1(day 7 after 1^st the booster vaccination), V2(day 14 after the 1^st booster vaccination), V3(day 28 after the 1^st booster vaccination), V4 (month 4 after the 1^st booster vaccination, the 2^nd booster vaccination), V5 (day 7 after 2^nd the booster vaccination), V6 (day 14 after 2^nd the booster vaccination), V7 (day 28 after 2^nd the booster vaccination) and V8 (month 6 after the 2^nd booster vaccination).

In “0-56 days” regimen, participants will attend 10 visits in total, including V-1(day 28 after the prime dose), V0 (day 56 after the prime dose, the 1^st booster vaccination), V1(day 7 after 1^st the booster vaccination), V2(day 14 after the 1^st booster vaccination), V3(day 28 after the 1^st booster vaccination), V4 (month 4 after the 1^st booster vaccination, the 2^nd booster vaccination), V5 (day 7 after 2^nd the booster vaccination), V6 (day 14 after 2^nd the booster vaccination), V7 (day 28 after 2^nd the booster vaccination) and V8 (month 6 after the 2^nd booster vaccination).

3.4 Sample size calculation

Sample size:

Hypothesis: GMT of vaccine group is superior to that in the control group at day 28 after the booster vaccination.

The baseline GMT level before the booster immunization is expected to be about 1:20 (log₁₀X=1.3) after one dose of prime vaccination with Ad5 vectored COVID-19 vaccine. After the booster dose, GMT level in the vaccine group is estimated to reach 1:60 (log₁₀X =1.78), while the control group remains 1:20. Assume that the Standard Deviation is about 4 (log₁₀X=0.6), and the allocation ratio for the vaccine group and placebo group is 2:1, then the minimal sample size to provide 80% power calculated is 40 and 20, respectively.

In each regimen group, subjects are stratified to two sub-age groups: 18-59 years and 60 years or above.

3.5 Randomization and blinding

3.6 Criteria for pausing or early termination

Criteria for pausing:

• - Occurrence of one or more ≥ grade 4 adverse reaction or serious adverse event that may be associated with vaccination;

• - Occurrence of grade 3 adverse events associated with vaccination in 10% of participants or more.

• - Administrative authority call for a complete termination of the trial and explain the reasons. investigators can terminate the study when any criteria for early termination is meet:

• - One or more ≥ grade 4 adverse reaction or serious adverse event occur that may probably associated with vaccination;

• - Occurrence of grade 3 adverse events associated with vaccination in 15% of participants or more (including injection-site reaction, systemic reaction, and vital signs and abnormal laboratory data;

• - The principal investigator call for a complete termination of the trial and explain the reasons;

• - Ethics committee call for a complete termination of the trial and explain the reasons;

3.7 Duration of study

It will take about 12 months for each participant from recruiting to completing the last visit.

4.1 Participants selection

Healthy people aged 18 and above who have been vaccinated of a dose recombinant COVID-19 Vaccine (Ad5 Vector), are selected as the target population, and informed in writing by informed consent approved by the ethics committee. On the premise that the volunteers themselves will sign the informed consent, they can only participate in the study after passing the physical examination and the following inclusion and exclusion criteria.

4.2 Inclusion criteria

• − The subjects over 18 years old who has completed one dose of recombinant Ad5 vectored COVID-19 vaccine;

• − The subjects can provide with informed consent and sign informed consent form (ICF);

• − The subjects are able to and willing to comply with the requirements of the clinical trial program and can complete the 6-month follow-up of the study;

• − Axillary temperature ≤ 37.0 ℃.

• − Individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigators and meet the requirements of these products immunization.

4.3 Exclusion Criteria

• − Have the medical history or family history of convulsion, epilepsy, encephalopathy and psychosis;

• − Be allergic to any component of the research vaccines, or used to have a history of hypersensitivity or serious reactions to vaccination;

• − Women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months;

• − Have acute febrile diseases and infectious diseases;

• − Have severe chronic diseases or condition in progress cannot be smoothly controlled, such as asthma, diabetes, thyroid disease;

• − Congenital or acquired angioedema / neuroedema.

• − Have the history of urticaria 1 year before receiving the trial vaccine.

• − Have asplenia or functional asplenia.

• − Have thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection);

• − Have the history of immunosuppressive therapy, antiallergy therapy, cytotoxic therapy or inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and acute corticosteroid therapy without dermatitis) over the past 6 months;

• − Have received blood products within 4 months before injection of trial vaccines;

• − Have received another investigational product within 1 month before injection of trial vaccine;

• − Have received attenuated vaccine within 1 month before injection of trial vaccine except the recombinant Ad5 vectored COVID-19 vaccine;

• − Have received subunit or inactivated vaccine within 14 days before the vaccination with trial vaccine;

• − Under anti tuberculosis treatment;

• − Not be able to follow the protocol, or not be able to understand the informed consent according to the researcher’s judgment, due to various medical, psychological, social or other conditions.

4.4 Withdraw from the study

Participants have the right to withdraw from the study at any time during the study period, and the investigators should record the reason of withdraw:

• − Loss of contact, early withdraw of the study;

• − Request to withdraw without any reason;

• − Withdraw for reasons unrelated to the study, such as long-term departure, relocation, etc., and the specific reason for withdrawal should be recorded;

• − Withdrawal for reasons related to the study, such as intolerance of adverse reactions, intolerance of biological specimen collection, etc., and the specific reason for withdrawal should be recorded. If a participant withdraw because of AE or SAE, investigators should follow up the participant until the resolve of AE or SAE.

• − Participants can require a complete withdraw from the study, all study behaviors can be stopped, including vaccination, biological specimen collection and safety observation. The data before withdrawal will not be used for analysis if he or she require so. If the participants allow the investigators use the data collected before the withdrawal, the data can be included in analysis;

• − Participants can require a partially withdraw from the study, such as refuse to vaccination or blood drawn only, but still participate in other procedures during the follow-up.

4.5 Complete of the study

4.6 Protocol violation and protocol deviation

5.4.1 Investigational vaccine

Investigational vaccine 1 (prime dose): the recombinant New Coronavirus vaccine (adenovirus vector) produced by CanSino Biologics Inc, liquid dosage form, 0.5 ml/ bottle, contains recombinant replication defective human 5 adenovirus 5×10¹⁰ virus particles expressing New Coronavirus S protein. Investigational vaccine 2 (booster dose): the New Coronavirus recombinant subunit vaccine (CHO cell) produced by Anhui ZhiFei Longcom Biopharmaceutical Co., Ltd., “Zhi Ke Wei De”, 0.5ml/ bottle, contains 25 μg NCP-RBD protein of New Coronavirus spike protein binding region NCP-RBD . “Placebo”: a Trivalent split influenza vaccine produced by Dalian Aleph Biomedical Co., Ltd., liquid dosage form, 0.5 ml/ bottle, contains 15 μg of H1N1, 15 μg of H3N2 and 15 μg of B-line hemagglutinin.

5.4.2 Administration

Subjects are vaccinated according to the immunization procedure. The vaccine should be fully shaken before use, and should be used immediately after opening. In case of cracks, unclear or invalid labels, or abnormal appearance of the vaccine, it should not be used.

The vaccines inject intramuscularly at the attachment of the lateral deltoid muscle of the upper arm, with priority given to the left arm.

5.4.3 Storage and transportation of investigational vaccines

1. Vaccine storage: investigational vaccines must be stored in a safe and locked place, and must not be contacted by unauthorized persons. The temperature of vaccine storage place should be controlled in the range of 2-8℃ to prevent freezing; the storage temperature of vaccine should be recorded once in the morning and afternoon of each working day.

2. Vaccine transportation: vaccines are transported from the research site to the vaccination site, from the vaccination site to the research site, and stored in the refrigerator or freezer. Each cold chain equipment is equipped with a thermometer. The vaccine administrator records the temperature every 30 minutes, and fills in the transportation and storage temperature records in detail. The storage temperature (2-8℃) must be kept during transportation. Any over temperature must be reported to the site responsible researcher or project coordinator for instructions. All vaccine transportation processes must be recorded.

5.4.4 Combined medication/vaccine

When the medical events happen during the study period, the participant are allowed to carry out the appropriate medical treatment, but the medical treatment should be recorded in time.

Other vaccination is not recommended except for emergency during the research period, such as rabies vaccine, tetanus vaccine, or other emergent vaccination need. Any vaccine used is required to be recorded during the study period.

5.5.1 Safety observation

After vaccination, the participants will stay at the clinic for 30-minute safety observation. The trained researchers should systematically observe each subject, record the local and systemic reactions within 30 minutes, and record the severity.

The participants are followed for the next a few days, and asked to record the safety observation by themselves on the diary card till 7 days after the vaccination. From the day 8 to the day 28 after vaccination, the adverse events are recorded passively. At the clinic visit, the researcher will retrospectively check and verified the adverse events recorded during the safety observation. From day 28 to month 6 after vaccination, the subjects are asked to report only serious adverse events during this period.

5.5.2 Safety observation contents and indicators

. Adverse events from the clinical trial are graded according to the guiding principles for the classification of adverse events in clinical trials of preventive vaccines (NMPA [2019] No. 102), as follows: (table 4-5)

General principles for the grading for other adverse events

The intensity of adverse events not mentioned in the rating table shall be evaluated according to the following criteria:

5.5.3 Outcome of AEs

The outcomes of ARs/AEs include: (1) Recovery; (2) Not yet recovered; (3) Recovered but sequelae; (4) Death; (5) Loss of visit.

5.5.4 Relationship between AE and vaccination

Investigators should make the best interpretation of AE, and assess the possible causal relationship between vaccination and reactions (such as history of underlying diseases, combined treatment of causation). This applies to all AEs, including severe ones and non-severe ones. The assessment of causality will be reasonably explained in the following or more aspects of the event: The similar reaction to the solution was observed in the past; identical events of similar types solution have been reported in the literature; the incident occurred along with the time of the vaccination, and again after the secondary vaccination According to definitions, all the solicited AE (that is, the local adverse event of the collection of the report) will be considered to be related to vaccination. The causal relationship of AE should be evaluated according to the following questions, and according to your judgment, the reasonable possibility of relationship between AE and vaccination is caused by the vaccination:

1. Related: there is a suspicion that a link between vaccine and the AE (do not need to be determined); the vaccine has a reasonable potential for promoting the AE.

2. Unrelated: there is no suspicion that a link exists between vaccine and the AE; there are other more likely causes, and vaccination has not been suspected to promote the AE.

5.5.5 Treatment of AEs/ARs

An adverse event (AE) is any untoward medical occurrence in a patient or clinical trial participant administered with a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

Adverse reactions (AR): unexpected or harmful reactions in the process of vaccination according to the prescribed dose and procedure, usually related to vaccination.

Serious adverse event (SAE): refers to the following important medical events, whether or not related to the vaccine clinical trial, including: 1) death; 2) life threatening; 3) hospitalization or prolonged hospitalization; 4) permanent or significant disability / loss of function; 5) congenital abnormality or birth defect; 6) severe adverse event It may lead to other important medical events, such as those listed above without treatment.

Suspected Unexpected Serious Adverse Reaction (SUSAR): Suspected adverse reactions refer to the adverse reactions of subjects at any dose that have nothing to do with the purpose of the medication. After analysis, it is considered that the relationship with the drug is at least likely to be related; Unexpected refers to adverse reactions. The nature, extent, consequences, or frequency are different from the expected risks described in the previous plan or other related materials (such as the investigator’s manual and instructions).

If subjects have any clinically significant disease/event after vaccination, it should be reported to the investigators as soon as possible. The investigators should follow up the adverse reaction/event until the symptoms disappear or the symptoms stabilize. When the investigators deem it necessary, treatment will be provided unconditionally to relieve the pain caused by the adverse reaction/event for the subjects. All medical treatments will be recorded at each follow-up.

In the event of a serious adverse event/reaction, the investigators should take necessary measures quickly, fill in the “Serious Adverse Event Report Form” within 24 hours, and report it to the principal investigator in the form of fax or E-mail.

5.5.6 Treatment of pregnancy events

Vaccination of the trial is not allowed during pregnancy. Before vaccination, the subjects will be given urine pregnancy test, and those who are positive in the urine pregnancy test should not be included in the group. If a pregnancy event occurs within 6 months of the visit, the Pregnancy Case Survey Form needs to be filled out.

5.6.1 Samples collection

“0-28 days” immunization regimen:

At V0 (day 28 after the prime dose and before the booster dose) and V3 (day 28 after the booster dose), 20 ml of venous blood will be collected by vacuum anticoagulant blood collection vessel. PBMC and serum will be separated to detect the antibody level, immune cell differentiation and antibody spectrum induced by the vaccine.

In V2 (day 14 after the booster dose) and V4 (month 6 after the booster dose), 10ml of venous blood will be collected by vacuum anticoagulant blood collection vessel, and the serum will be separated to detect the antibody level, immune cell differentiation and antibody spectrum induced by the vaccine.

“0-56 days” immunization regimen:

At V-1 (day 28 after the prime dose) and V3 (day 28 after the booster dose), 20 ml of venous blood will be collected by vacuum anticoagulant blood collection vessel. PBMC and serum will be separated to detect the antibody level, immune cell differentiation and antibody spectrum induced by the vaccine.

At V0 (day 56 after the prime dose and the booster dose), V2 (day 14 after the booster dose) and V4 (month 6 after the booster dose), 10ml of venous blood will be collected by vacuum anticoagulant blood collection vessel, and the serum will be separated to detect the antibody level, immune cell differentiation and antibody spectrum induced by the vaccine.

The serum samples of this clinical trial will be used to evaluate the immune response level of the research vaccine. For other studies, the approval of the ethics committee and the consent of the subjects are required.

5.6.2 Preservation and transportation of samples

Unified operation standards are adopted in the process of preservation and transportation. The storage temperature of serum should be - 20℃ and below, and it should be transported to the testing laboratory in time. The separation, transportation and preservation of BPMC used for the differentiation of immune cell population and the detection of antibody spectrum are operated by the third party laboratory according to the standard operating procedures.

5.7.1 Data collection, entry and reporting

Vaccination and visit records and other original data should be clearly recorded, which should be filled in with a black signature pen. The errors of the original records should not be wiped or covered, but should be crossed off, put the corrected data aside, and signed and dated by the investigators.

Fill in all the case report forms according to the protocol. Case report form is used to record the data of clinical trials. It is an important part of clinical trials and research reports. It should be filled in clearly and completely. It is required to fill in with a black signature pen. The mistakes should not be erased or covered by the original record. Instead, a horizontal line should be drawn on it, and the corrected data should be indicated in the blank beside it. The revised researcher should sign his name and indicate the date.

According to the requirements of the scheme, data collection, biological sample collection and examination should be carried out in each visit time window, and the original documents and records should be complete, and the examination conclusions should be entered into the case report form (CRF) in time.

5.7.2 Verification of data records

The quality controller should check the data record regularly and irregularly until the CRF is completed. Before withdrawing the CRF, the quality controller should carefully check the CRF number of the subjects, the number of pages of each CRF and the necessary signature of the researcher. The main content of quality control should focus on the following links: signing of informed consent, volunteer screening, immunization, management of experimental vaccine, safety observation, collection and preservation of immunogenic samples, etc. the consistency of research data and original data should be focused on, and manual verification should be carried out. The verification results shall be recorded. The transfer of CRF and other research materials should be documented.

5.7.3 Database establishment and data entry

Establishment of database:

The personnel in charge of data management shall establish the database structure and check procedures according to CRF, ensure that the database can be correctly converted to SAS file format, and modify and confirm the database structure through trial input.

Further verification of CRF:

Before entering CRF, data management personnel should check CRF again, mainly to see if there are omissions and obvious errors.

Data entry:

After the training of data entry personnel, data entry is carried out by two persons and two computers.

Data comparison and examination:

Check the consistency of the database data independently completed by the two people, report the inconsistent values and information, and then check the original data item by item to correct until the two databases are consistent. Use the computer program that has been written and confirmed to logically check the data, issue the query form and ask the researcher to confirm and then modify the database until there is no doubt. It is necessary to select a certain number of CRF randomly according to a certain proportion to control the quality of the database, and compare with the data in the database manually, so as to ensure that the data in the database is consistent with the CRF content.

5.7.4 Database locking

Before statistical analysis, it is necessary to conduct a check and clean of the database. The analyzed population will be set according to the definition of the data sets, including the FAS set, PPS set and safety analysis data set, and to determine the deviation from the regimen and its impact on the analysis data set. After the database is cleaned, the database will be locked, and the statistical analysis plan is locked at the same time.

5.8.1 Statistical plan

The statistical analysis of this study will be completed in two stages. After the subjects complete the visit 28 days after the booster dose immunization, the study database will be recorded, reviewed and locked for the first stage statistical analysis.

The safety and immunogenicity data after 28 days till 6 months after immunization will be collected, reviewed and locked for the second stage statistical analysis and summary.

5.8.2 Selection of analysis data sets

Safety data set (SS):

The safety evaluation should be conducted for all participants who receive vaccines after randomization. Data violating the protocol should not be eliminated.

Immunogenicity data set:

Full Analysis Set (FAS): It is defined as ideal participant population determined according to the ITT (Intention-to-treat analysis) principle, all participants who meet the inclusion / exclusion criteria, and are randomized and given vaccine and have at least one post-immunization blood test results are included in the FAS.

Per-Protocol Set (PPS): It is a subset of FAS. Participants in this set are more compliant with the protocol, experience no major protocol violation, comply with all inclusion criteria / exclusion criteria, and complete the vaccination within the time window as required in the protocol and all blood samplings are included in the PPS set. Participants who violate the trial protocol, such as poor compliance or lost to follow-up, and those who suffer intercurrent SARS-CoV-2 infection will not be included in this analysis set.

In this trial, the FAS will be used as the primary analysis set. However, PPS should be analyzed simultaneously. Any inconsistency between PPS and FAS analysis results should be discussed in the report.

5.8.3 Data statistics method

During statistical analysis, first, the number of completed cases and drop-out cases should be checked. Then demographic and baseline characteristics of each group at enrollment should be analyzed to investigate intergroup comparability. Efficacy evaluation of vaccine includes the determination of evaluation indicators and intergroup comparison of efficacy. Safety evaluation includes the statistics of clinical ARs/AEs.

Participant elimination criteria: participants don’t meet the inclusion criteria; data and information after vaccination are not followed up; information and data after randomization are seriously missing; participants meet exclusion criteria but are not withdrawn; participants receive wrong vaccination or incorrect dose.

Safety analysis in this trial mainly includes descriptive analysis of the incidence of ARs/AEs. χ² test may be carried out for intergroup comparison, and Fisher’s exact test may be performed if necessary. After immunization, the number of case-times and person-times of local AEs in the high-dose group will be calculated (with conventional calculation method). The number of person-times will be calculated based on the highest severity in both arms, and the number of case-times will be calculated based on the cumulative local AEs actually occurring at the vaccination site. Logarithmic transformation is required for analysis of immunogenicity indicator of antibody level which should be expressed as GMT, standard deviation, median, maximum and minimum and 95% confidence interval. Classification indicators will be compared between groups. Antibody seroconversion rate will be analyzed by χ² test and Fisher’s exact test may be used if necessary. Study data at different time points will be analyzed with statistical analysis for repeated measurement data.

SAS 9.4 is adopted for all statistical analyses with two-sided test. The P value is directly calculated while carrying out Fisher’s exact test when test statistics and corresponding P values are given, and in case of P ≤ 0.05, the difference is statistically significant.

6.1 Quality assurance and quality control

Carry out on-site quality control in strict accordance with the relevant requirements of Good Clinical Practice (GCP).

Investigators in some positions are qualified as physicians or above. Prior to the clinical trial, they will be trained in the clinical protocol and all trial procedures, including information about the trial vaccine, procedures for obtaining informed consent, operating procedures for each position, and procedures for reporting adverse reactions/events.

The data of each subject is reviewed at each stage of the clinical trial to ensure that the content of the clinical trial meets the requirements of the protocol and that the obtained data are complete and reliable. The quality controller controls the whole process of the clinical trial.

All the work on site are carried out strictly in accordance with the clinical trial field operation manual. Each subject records the “Diary Card” by themselves, follows up and retrospectively investigats by the researcher, and reviews and guides the filling in of the “Diary Card”.

The quality controller shall conduct a comprehensive check on the original data, and after training, a special person shall enter the data of eCRF. The double entry method shall be adopted and completed by two people independently.

Calibration or standardization of the instruments used in this clinical trial.

6.2 Modification of clinical protocol

After this plan is approved by the Ethics Committee, if there is any major modification in the implementation process, it shall be reported to the Ethics Committee for approval before it can be implemented. The investigators shall not execute any deviation or change without the consent of the Sponsor and prior review and written approval of the Ethics Committee (EC).

Any changes to the scheme, whether material or non-material, are required to be in writing. EC approval is required to identify substantive protocol changes that would affect the safety of subjects, the scope of the study, or the scientific quality of the study.

6.3 Scheme deviation

The investigators shall carry out the clinical trial according to protocol approved by the ethics committee and the provisions of GCP. During the trial, the researcher shall not deviate from the protocol unless the harm to the subjects is eliminated.

The research center shall record all protocol deviations in the original data of subjects, including but not limited to the occurrence time of protocol deviation, discovery time, event description and measures, etc. In case of serious protocol deviations, the main researchers should be informed in time and report to the IEC.

6.4 Confidentiality

The sponsor, investigators, IEC, or a fully authorized representative of regulatory authority should have the right to obtain data related to the clinical trial, but relevant content cannot be used for any other clinical trials, nor can it be disclosed to any other individuals or entities.

Investigators must sign a confidentiality agreement to confirm that he/she knows and agrees to hold the information of this study confidential.

Investigators and other study personnel should keep all information provided by the sponsor and all data/information generated at the study site (except for medical records of participants) confidential. Such information and data should not be used for any purposes other than the study. This restriction does not apply to: (1) study information is not disclosed because of violations by investigators and researchers; (2) study information is disclosed only to the IRB/IEC for the purpose of study evaluation; (3) study information is disclosed to provide appropriate medical assistance to participants.

8.1 Ethical Review and Approval

The PI should submit the clinical trial protocol and all necessary additional documents to the IEC for initial review:

• - Clinical study protocol (indicated with version No. / date)

• - Informed Consent Form (indicated with version No./date)

• - Participant recruitment materials (indicated with version No. / date)

• - Diary card (indicated with version No. / date)

• - Contact card (indicated with version No. / date)

• - Vaccination Visit Record (indicated with version No./date)

• - PI’s CV

• - Drug clinical trial approval from the NMPA

After the above study documents are reviewed and approved by the IEC, a written approval certificate will be issued to the investigators.

8.2 Follow-up Review

Whether the methods for inclusion of participants and the information provided to participants are complete and understandable; whether the methods for obtaining informed consent are appropriate; whether SAEs are reported timely; and whether timely medical treatment can be provided for the SAE related to inoculation with the candidate vaccine.

During the whole trial, the IEC should supervise whether the risk-benefit ratio of the study is increased and whether the rights and interests of participants are effectively protected.

8.3 Potential risks and minimization of risks